News Medical on MSN

p38 MAPK drives epigenetic activation of fibrotic genes in lung fibroblasts

A new research paper was published in Volume 18 of Aging-US on March 3, 2026, titled "P38 MAPK is involved in epigenetic regulation of fibrotic genes in replication induced senescence in lung ...
Cure Today

Dosing of PAS-004 Begins in Patients in MAPK-Driven Tumors

PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
ascopubs.org

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
ascopubs.org

A phase 1/2 study of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations.

Phase 1 study of C019199, an oral CSF-1R/DDRs/VEGFR2 multiple kinase inhibitor, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, ...